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Abstract: Squamous Cell Carcinoma-derived Stem-like Cells (SCC-SC) originate from alterations
in keratinocyte stem cells (KSC) gene expression and sustain tumor development, invasion and
recurrence. Since survivin, a KSC marker, is highly expressed in SCC-SC, we evaluate its role in
SCC-SC cell growth and SCC models. Survivin silencing by siRNA decreases clonal growth of SCC
keratinocytes and viability of total, rapidly adhering (RAD) and non-RAD (NRAD) cells from primary
SCC. Similarly, survivin silencing reduces the expression of stem cell markers (OCT4, NOTCH1,
CD133, β1-integrin), while it increases the level of differentiation markers (K10, involucrin). Moreover,
survivin silencing improves the malignant phenotype of SCC 3D-reconstruct, as demonstrated by
reduced epidermal thickness, lower Ki-67 positive cell number, and decreased expression of MMP9
and psoriasin. Furthermore, survivin depletion by siRNA in RasG12V-IκBα-derived tumors leads
to smaller tumor formation characterized by lower mitotic index and reduced expression of the
tumor-associated marker HIF1α, VEGF and CD51. Therefore, our results indicate survivin as a key
gene in regulating SCC cancer stem cell formation and cSCC development.
Keywords: squamous cell carcinoma; stem cells; β1-integrin; tumor formation; survivin; rapidly
adhering cells; skin; tumorigenesis; differentiation
1. Introduction
Cutaneous squamous cell carcinoma (cSCC) represents one of the most frequent skin cancers, and
together with the basal cell carcinoma (BCC), account for over 1 million new cancers annually in the
United States [1]. Surgical resection is curative in 95% of patients with early diagnosis and leads to
complete eradication of the tumor. However, this neoplasia may display aggressive histopathologic
behavior and undergo relapse and/or perineural or lymphovascular invasion, suggesting that further
studies on the mechanisms underlying cSCCs formation are needed.
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The most recent models explaining cellular origin and maintenance of tumors indicate
a population of stem-like cells, also defined cancer stem cells (CSC), as a “starting point nucleus” for
the development of a neoplasia, thus determining its heterogeneity and complexity and affecting
tumor development, metastatic behavior and recurrence [2–4]. In skin, the oncogenic transformation
of the keratinocyte stem cells (KSC), due to genetic or epigenetic alterations [5], gives origin to the
SCC-derived Stem-like Cells (SCC-SC), which are responsible for the development of papillomas and
cSCC [4].
Since the epidermis is a continuously renewing tissue, it is reasonable that any damage occurring
in any cells other than stem cells will be rapidly eliminated during the process of epidermal
differentiation or apoptosis. Recent studies involving the use of the two-step mouse model of skin
carcinogenesis, supports the fact that KSC are targets of both chemical and physical carcinogens and
promoters, and determine the formation of papillomas and carcinomas [6]. In particular, cSCC easily
develop from the graft of v-rasHa or v-rasHa–IκBα transformed keratinocytes onto nude mice [7–9],
and the slow-cycling, quiescent, poorly differentiated (stem cells), but not the rapidly proliferating
transit amplifying cells, give rise to more aggressive and invasive tumor [6,10], therefore acting,
once transformed, as cancer stem cells.
The isolation of normal KSC is complicated by the absence of definite markers; however, several
molecules, such as β1-integrin/CD46, α6-integrin/CD71 or survivin [11] have been successfully used
to identify KSC and to obtain a population enriched in KSC in culture [12–14].
In particular, survivin, an IAP protein, is specifically expressed by the high proliferative KSC
subpopulation [15] and dually acts on cell cycle regulation and as anti-apoptotic molecule. Survivin
functions depend on its intracellular localization [16]: while nuclear survivin is mostly associated with
cell division complexes and is essential to mitosis, the mitochondrial/cytoplasmic pool negatively
affects caspase activation and is considered as cytoprotective [17]. The high level of survivin is
predictive for higher malignancy or poor outcome when analyzed in epithelial tumors [18–21].
In particular, precancerous and cancerous skin lesions, including cutaneous SCC, presents higher levels
of nuclear survivin that is associated with a lower differentiation and a more invasive phenotype [22].
Taking advantage of the KSC isolation method based on β1-integrin expression and adhesion to
collagen IV-coated plates, primary human cSCC subpopulations with specific properties within the
tumor context, have been recently isolated and characterized [22]. These cells have been divided in
rapidly adhering (RAD) and non-RAD (NRAD) cells. In particular, RAD cells present stem cell features
and work as SCC-SC. They show higher clonogenic ability and, once inoculated in mice, they generate
bigger tumors with highly aggressive behavior.
In this study, we evaluated the role of survivin within primary human cSCC, by analyzing RAD
and non-RAD cSCC keratinocytes, as well as cSCC bulk cells. We present evidence that survivin
expression increases the malignant phenotype of cSCC, since its functions specifically interfere with
RAD cell viability and proliferation as well as with tumor development in vivo.
2. Results and Discussion
2.1. Survivin Expression Affects cSCC Severity in Vitro
We had previously demonstrated that survivin expression, which identifies KSC in vitro, is higher
in RAD keratinocytes with respect to NRAD and cSCC bulk cells [22]. This is in agreement with the
increased levels of survivin in tumors, in fetal tissues and in stem cells from normal and pathological
adult tissues [23,24], and correlates with survivin expression in cSCC lesions [25]. In addition,
in keeping with these findings, survivin is involved in chemo and radio-resistance in cancer stem
cells [26] and regulates the balance between survival and apoptosis in neural stem cells and glioma
CSC [27]. This is functionally relevant to support survivin role within cSCC development and
cSCC-SC maintenance.
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To evaluate the facets of survivin role in cSCC keratinocytes, we utilized a gene expression
silencing approach, by survivin siRNA, to remove the endogenous survivin in cSCC cells from primary
tumors. While scramble transfected cells grow exponentially with time, survivin depleted cells display
a slow rate of proliferation, as shown by vital cell analysis (Figure 1A), and give rise to a significantly
lower amount of colonies with bigger size (Figure 1B,C). In association with the short and long term
proliferative potential, survivin expression knocking-down in cSCC primary cells correlates with
the decreased expression of stemness-associated markers, such as OCT-4, NOTCH1, CD133 and
β1-integrin [22,28–31] (Figure 1D). Interestingly, NOTCH1-survivin axis in the maintenance of human
keratinocyte stemness [30] appears to be preserved also in the context of tumor cells. On the other hand,
the expression of early epidermal differentiation markers, such as keratin 10 (K10) and involucrin, was
increased (Figure 1D). Moreover, by looking closely at the cSCC subpopulation, survivin silencing
has the strongest effect on RAD cell density with respect to cSCC bulk and NRAD cells (Figure 1E,F).
These results provide evidence of the important role of survivin in the preservation of cSCC-SC pool,
breaking down their proliferative potential and, therefore, influencing cSCC tumor aggressiveness.
Figure 1. Survivin inhibition decreases cSCC cell proliferation, clonogenic ability and stemness
features. (A) cSCC cell ability to proliferate in vitro after transfection with scramble or survivin
siRNA was evaluated by MTT (3-4,5-dimethylyhyazol-2-y1)-2,5-diphenyltetrazolium bromide) assay;
(B) Clonal growth assessment of cSCC cells after transfection with scramble or survivin siRNA by
CFE. CFE was performed in triplicate in three independent experiments and quantified; ** p < 0.01;
(C) Percentage of colonies with respect to size obtained from CFE assay; (D) Expression of stem cell and
differentiation markers in scramble or survivin siRNA transfected cSCC cells. Cells were analysed 24 h
after transfection, and levels of markers were determined by Western blot analysis. β-actin was used
as loading control; (E) Representative pictures of RAD, NRAD and cSCC bulk cells after transfection
with scramble or survivin siRNA, 24 h post-treatment. Scale bar = 200 µm; (F) Relative cell density
evaluated by ImageJ software analysis (* 0.01 < p < 0.05; ** p < 0.01).
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2.2. Survivin Downregulation Decreases SCC Aggressiveness in 3D-Models
To better define how survivin expression correlates with cSCC morphology and differentiation,
we prepared 3D skin reconstructs from SCC13-derived RAD and NRAD cells after transfection
with survivin siRNA. The efficiency of survivin silencing as compared to control was evaluated
by immunohistochemical staining and survivin positive cell count (data not shown).
It has been shown previously that skin equivalents generated with cSCC cell lines display
extensive dermal invasion and altered attachment of the epidermal keratinocytes to the dermis [32].
These 3D reconstructs were characterized by epidermal hyperproliferation, higher expression
of proliferation-related markers and misregulated differentiation. In our model, we were able
to recapitulate the morphological features of cSCC. At the histological level, both RAD and
NRAD-derived skin equivalents showed squamous keratinocytes, epidermal hyperplasia and dermal
invasiveness. Survivin-depleted cSCC cells gave origin to a thinner epidermis, with significant
reduction of epidermal thickness in RAD-derived skin equivalents, and decreased dermal-invading
areas (Figure 2A).
Figure 2. Survivin depleted RAD and NRAD-derived skin reconstructs. (A) Left panel: Hematoxilin
and Eosin staining of survivin siRNA-treated RAD and NRAD SCC13 derived skin reconstructs.
Right panel: Bar graph representing epidermal thickness (micron) of survivin siRNA-treated RAD and
NRAD SCC13 derived skin reconstructs. Scale bar = 120 µm; (B) Bar graph representing the number
of Ki-67 positive cells; (C) MMP9 and psoriasin expression evaluated by immunohistochemistry in
siRNA-treated RAD and NRAD SCC13 derived skin reconstructs, with the table indicating the relative
scores: - not expressed; + poorly expressed; ++ moderately expressed; +++ well expressed. The images
are representative of three independent experiments. (* 0.01 < p < 0.05; ** p < 0.01). Scale bar = 120 µm.
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Consistently, survivin silencing decreased the number of Ki-67 positive cells in both RAD and
NRAD SCC reconstructs (Figure 2B), thus demonstrating survivin ability to modulate the proliferative
capacity of SCC13 keratinocytes in the 3D skin model in vitro. Most importantly, the proliferative
brake was more efficient in RAD with respect to NRAD SCC reconstructs, whose derived tumors have
been previously shown to have a lower number of Ki-67 positive cells and a reduced mitotic index,
as compared to RAD tumors [22].
The release of metalloproteinase-9 (MMP-9), which correlates with invasion and metastasis [33,34],
resulted significantly reduced in survivin-silenced SCC13 skin equivalent (Figure 2C). These findings
are in agreement with the demonstration that, in the presence of survivin overexpression, cSCC are
more aggressive and display higher metastatic potential, thus correlating with a poor prognosis [25].
On the other hand, in the absence of survivin, the malignant phenotype of cSCC epidermal reconstructs
was significantly ameliorated, as demonstrated by the strongly decrease of S100A7 (psoriasin)
expression (Figure 2C), which is a recognized marker of poor prognosis in epithelial cancers and
is significantly upregulated in human epithelial skin tumors [35,36].
Therefore, these data demonstrate that survivin affects SCC cancer cell stemness property,
by regulating the proliferative potential and aggressiveness of SCC cells.
2.3. Survivin Expression Is Crucial in Tumor Aggressiveness
Human skin cancers, such as BCC and SCC, mostly arise from KSC coming from interfollicular
locations in human skin [37–39]. About 20%–25% of sporadic cSCC lesions have activating mutation
in RAS [40] and the expression of the Ha-RasG12V allele in normal human keratinocytes produce a set
of biochemical and morphological modifications, which lead to cell cycle block at the G1 phase
and to the accumulation of senescent cells [41]. This block could be bypassed by using CDK4
(cyclin-dependent kinase 4) overexpression or the inhibition of NFkB activation through IκBα [9,41].
The coexpression of RasG12V and IκBα (RasG12V-IκBαM) in human keratinocytes used to regenerate
skin in immuno-deficient mice promote the formation of rapidly growing tumors resembling SCC [9].
Therefore, in order to analyze the role of survivin in human cSCC formation and progression
in vivo, we used a model where human primary neonatal keratinocytes were infected with retroviral
vectors expressing the oncogenic Ras (Ha-RasG12V) and the inhibitor of NFκB (IκBαM), and
subsequently transfected with survivin siRNA before injection on the flank skin of CB17-SCID mice.
This model allows a direct evaluation of the malignant transformation of human keratinocytes,
therefore limiting the differences between human and mouse skin in the context of tumor
development [37].
After checking survivin depletion by Western Blot analysis, we found that the expression of
Ha-RasG12V-IκBαM in keratinocytes promoted survivin upregulation (Figure 3A), which is in line
with the induction of the oncogenic phenotype in keratinocytes and the higher level of survivin in
cancer cells [42]. This is also in agreement with Ras-dependent upregulation of survivin in HaCaT
cells [43,44] and normal K-Ras promoted survivin degradation [45].
According to survivin role in promoting RAD/cSCC-SC maintenance, survivin depletion
in RasG12V-IκBαM-transduced keratinocytes produced a statistically significant reduction of cell
proliferation (Figure 3B). These cells were successfully used for tumorigenesis experiments in vivo.
Tumors derived from survivin-silenced RasG12V-IκBαM-transduced keratinocytes and control cells
(referred as NoLacZ) were evaluated for survivin, keratins, H-Ras and IκBαM expression to confirm the
epithelial origin and the efficiency of infection (Figure 3C). While there is no difference in size between
tumors generated by survivin or scramble siRNA treated control cells, RasG12V-IκBαM keratinocytes
give rise to a substantially smaller tumor in the absence of survivin silencing (Table 1). Moreover,
in the presence of survivin siRNA, all cases (3/3) of injected RasG12V-IκBαM keratinocytes do not
create tumors at four weeks (Table 1).
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Figure 3. Survivin silencing decreases cell viability in RasG12V-IκBαM-transduced keratinocytes.
(A) Expression of survivin in scramble or survivin siRNA transfected NoLacZ or RasG12V-IκBαM-
transduced keratinocytes. Cells were analysed 48 h after transfection, and levels of markers were
determined by Western blot analysis. β-actin was used as loading control; (B) Survivin siRNA
transfected NoLacZ or RasG12V-IκBαM-transduced keratinocytes ability to proliferate in vitro evaluated
by MTT assay 72 h after transfection; (C) Survivin, pan-keratin, H-Ras and IκBα staining in
survivin siRNA transfected NoLacZ or RasG12V-IκBαM tumors evaluated by immunofluorescence.
(** = p < 0.01). Scale bar = 200 µm.
Table 1. Evaluation of in vivo tumor formation after sub-cutaneous injection of human keratinocytes
infected with retroviral vector expressing Ha-RasG12V and IκBαM in presence or in absence of
endogenous survivin.
Condition Tumour at 4 Weeks Tumour at 6 Weeks Tumour Size (cm3 ˘ SD)
NoLacZ Scramble ´ (3/3) + (3/3) 0.49 ˘ 0.17
NoLacZ Survivin siRNA ´ (3/3) + (3/3) 0.39 ˘ 0.14
RasG12V-IκBαM Scramble + (3/3) + (3/3) 0.89 ˘ 0.33
RasG12V-IκBαM Survivin siRNA ´ (3/3) + (3/3) 1.01 ˘ 0.38
Moreover, RasG12V-IκBαM/scramble siRNA-tumors displayed less alterations at the nuclear level
with respect to RasG12V-IκBαM/survivin siRNA-tumors (Figure 4A), with bigger nuclei and prominent
nucleoli, which correlates with survivin implications in chromosomal stability and segregation [46],
as well as a higher mitotic index (Figure 4B). Moreover, the analysis of the cancer associated
markers HIF-1α, VEGF and CD51 (αv-integrin) [47–49] strongly support the implication of survivin
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overexpression in favor of a poor tumor prognosis. In particular, the upregulation of HIF-1α and
VEGF promoted by RasG12V-IκBαM was inhibited by survivin depletion (Figure 4C,D,F upper panel).
Similarly, the number of CD51 positive cells that was increased by RasG12V-IκBαM expression, was
restored to NoLacZ levels in RasG12V-IκBαM/survivin siRNA tumors (Figure 4E,F lower panel). These
results further indicate the critical role of survivin within skin tumorigenesis and the importance of
targeting survivin in SCC-SC in order to get a significative improvement of the cutaneous neoplasia.
Figure 4. Survivin silencing decreases the malignant phenotype of RasG12V-IκBαM-derived
tumors. (A) Hematoxilin and Eosin staining of survivin siRNA-treated RasG12V-IκBαM-derived
tumors; (B) Mitotic Index representing the number of cells undergoing mitosis over total cells.
Scale bars = 200 µm; (C) HIF1α staining in survivin siRNA transfected NoLacZ or RasG12V-IκBαM
tumors evaluated by immunofluorescence; (D) VEGF staining in survivin siRNA transfected NoLacZ
or RasG12V-IκBαM tumors evaluated by immunofluorescence; (E) CD51 staining in survivin siRNA
transfected NoLacZ or RasG12V-IκBαM tumors evaluated by immunofluoresce; (F) HIF1α (upper panel)
and CD51 (lower panel) positive cell count assessed by ImageJ software (* 0.01 < p < 0.05; ** p < 0.01).
Scale bars = 200 µm.
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3. Materials and Methods
3.1. Isolation of Primary Keratinocytes from cSCC Tissues
Primary keratinocytes from human cSCC were isolated as previously described [22]. Briefly,
ten tumor samples (as biological replicates) from human cSCC patients were surgically removed and
immediately stored in a sterile test tube containing medium and antibiotics. All tumor samples were
collected with written informed consent of patients, according to the Declaration of Helsinki after
approval of the Modena Medical Ethical Committee. Tumor tissues were washed with PBS without
calcium and magnesium, cut into small fragments and digested in DMEM (Dulbecco’s Modified Eagle
Medium) containing 200 U/mL type I collagenase, 200 U/mL dispase and 70 U/mL DNase shaking
for 2 h at 37 ˝C. The digested top tissue mixture was then filtered and centrifuged to collect the cells.
Total cells were then seeded onto 3T3 feeder layers as previously described [50] and primary and
secondary cell cultures were obtained.
For RAD and NRAD cells isolation, collagen IV coated plates were prepared by seeding a human
placenta-derived collagen IV solution (100 µg/mL, Sigma-Aldrich, St. Louis, MO, USA). Total cells
from cSCC cultures, either at passage 0 or 1, were seeded on collagen IV pre-coated dishes for 5 min.
Cells adhering within 5 min represent RAD cSCC keratinocytes; in order to analyze RAD and NRAD
cellular morphology, after cell separation, NRAD and bulk cells were collected and seeded on a dish
of the same size as the one used for the separation; pictures have been taken within 10 min from
the separation process. For in vitro proliferation/viability, clonogenic assays or 3D skin reconstruct
after transfection with scramble or survivin siRNA (Dharmacon Inc, Lafayette, CO, USA) cells were
maintained in culture with serum-free keratinocyte growth medium (KGM) until they reached the
desired confluence.
3.2. Isolation of Primary Keratinocytes from Healthy Skin and SCC Cell Line Culture
Normal human keratinocytes were isolated from healthy skin biopsies obtained from waste
materials from Surgical Room. Patient consent for experiments was not required because Italian laws
consider human tissue left over from surgery as discarded material. Isolated cells were cultured as
described by Pincelli and colleagues [15]. Cells were maintained in culture with KGM until confluence
and utilized for in vivo tumorigenesis assay. SCC13 cell line were purchased from ATCC (Teddington,
UK) and maintained in culture with KGM.
3.3. siRNA Transfection of Keratinocytes
cSCC cells (RAD, NRAD or bulk cells), human keratinocytes transduced with RasG12V-IκBαM
or control vector (NoLacZ) or SCC13 were plated in antibiotic-free KGM medium in order to get
sub confluent conditions 24 h post-seeding. Cells were transfected twice with 25 nM scrambled
or survivin siRNA (ON-TARGET plus SMARTpool code L003459, Dharmacon Inc., Lafayette, CO,
USA), combined with Lipofectamin 2000 and Opti-MEM (Thermo Fisher, Waltham, MA, USA), as the
datasheet suggests. Cells were evaluated at different time points or further seeded according to the
specific experiment requirements.
3.4. Detection of Cell Viability by MTT
cSCC bulk cells (5000/well) or human keratinocytes transduced with RasG12V-IκBαM or control
vector (NoLacZ) were seeded in a 96-wells plate and transfected with scramble or survivin siRNA 24 h
post plating. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma-Aldrich,
St. Louis, MO, USA) assay was performed at 24 h, 48 h, 72 h and 96 h post transfection or 72 h,
according to the specific experiment requirements. The results are expressed as fold increase respect to
scramble treated cells at 24 h or as Optical Density (OD) plotted against time. Results are calculated as
the mean SD of three different experiments.
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3.5. Colony Forming Efficiency (CFE)
cSCC bulk cells were transfected with scramble or survivin siRNA and subcultured on a feeder
layer composed of mytomicin C (Sigma-Aldrich, St. Louis, MO, USA)-treated 3T3 cells at a density
of 100 cells per dish 24 h post-transfection. Fourteen days later, dishes were fixed with 10% buffered
formalin and stained with crystal violet. Colonies were manually scored. The results were expressed
as percentages of the number of cells plated in each dish or number of colonies for each size and
represented as the mean ˘ SD of three independent experiments.
3.6. Western Blotting (WB)
Total proteins from siRNA-transfected cSCC bulk cells or siRNA-transfected RasG12V-IκBαM or
control vector (NoLacZ) were extracted with RIPA (Radioimmunoprecipitation assay) lysis buffer
containing protease inhibitors. Equal amounts of protein from each sample were run through a 6%–18%
SDS–PAGE gel and transferred onto a nitrocellulose membrane. Briefly, membranes were incubated
overnight at 4 ˝C with the following primary antibodies: rabbit polyclonal anti-human survivin (1:1000;
Novus Biologicals, Littleton, CO, USA), or rabbit polyclonal anti-human NOTCH1 (1:500; Abcam,
Cambridge, UK), or rabbit anti-human OCT4 (1:1000; Novus Biologicals, Littleton, CO, USA), mouse
anti-human CD133 (1:200; Miltenyi Biotec Inc., Auburn, CA, USA), mouse anti-human β1-integrin
(1:500; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), or mouse monoclonal anti-human
involucrin (1:1500; Sigma-Aldrich), or rabbit polyclonal anti-human Keratin 10 (1:5000; Epitomics
Burlingame, CA, USA) or mouse monoclonal anti-human β-actin (1:5000; Sigma-Aldrich). After
3 washes with a PBS/tween solution, membranes were then incubated with secondary antibodies:
goat anti-mouse or goat anti-rabbit (1:3000; Bio-Rad Laboratories, Hercules, CA, USA) for 45 min at
room temperature. Bands were then visualized with chemiluminescence detection system (Amersham
Biosciences UK Limited, Little Chalfont Buckinghamshire, UK). The band intensity was quantitatively
determined using ImageJ software (Wayne Rasband, National Institute of Mental Health, Bethesda,
MD, USA), and protein levels’ intensity was normalized to β-actin expression.
3.7. H and E Staining and Mitotic Index Calculation
cSCC skin reconstruction or tumors were removed from animals, placed in 4% buffered formalin
for no more than 24 h, and then embedded in paraffin. Serial tissue sections (4 µm thick) were
deparaffinized, hydrated in xylene and graded alcohol solutions. For H and E stains, Mayer
hematoxylin and Eosin Y Alcoholic were used. Staining times were 5 min for hematoxylin and
1 min for eosin. Slides were covered with coverslips with the addition of aqueous mount. The mitotic
index was calculated and expressed as the ratio between the number of cells in mitosis and the total
number of cells on H and E sections.
3.8. Immunohistochemistry
cSCC skin reconstruct were fixed with formalin for 2 h at room temperature, dehydrated and
embedded in paraffin. The staining was performed using the UltraVision LP Detection System AP
Polymer & Fast Red Chromogen assay (Thermo Fisher Scientific, Waltham, MA, USA), according to
the manufacturer’s instructions. Briefly, slides were treated with Ultra V Block and samples were
incubated with anti-Ki-67 (1:200; Epitomics, Burlingame, CA, USA), or anti-keratin (ready to use; Cell
Marque), or anti-MMP9 (1:100; Abcam, Cambridge, UK) or anti-psoriasin (1:50, Abcam, Cambridge,
UK) for 1 h at room temperature.
After washes in PBS, Primary Antibody Enhancer (Thermo Fisher Scientific, Waltham, MA, USA)
was added for 20 min at room temperature, followed by incubation with AP Polymer anti-mouse/rabbit
IgG for 30 min at room temperature. Slides were stained with Fast Red using Naphthol Phosphate
as substrate. Samples were analyzed under a conventional optical microscope (Zeiss Axioskope 40,
Carl Zeiss, Jena, Germany).
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3.9. Immunofluorescence
Four micrometer skin sections from formalin fixed-paraffin tumors were rehydrated in PBS buffer
and permeabilized by incubation for 10 min with 0.5% Triton X-100. Then, slides were incubated for
15 min with 0.5% bovine serum albumin and 5% goat serum, and for 60 min at 37 ˝C with the rabbit
polyclonal anti-human Survivin antibody (1:50, Novus, Bloomington, MN, USA) or HIF1α (1:500,
Novus, Bloomington, MN, USA), VEGF (1:50, Thermo Fisher Scientific, Waltham, MA, USA), CD51
(1:50, Abcam, Cambridge, UK). After four washes in PBS, samples were incubated for 60 min with
the anti-rabbit secondary antibody, Alexa Fluor 546 (1:100, Thermo Fisher Scientific, Waltham, MA,
USA). Fluorescent specimens were analyzed by confocal scanning laser microscope (Leica TCS SP2)
and positive cell counts were performed by ImageJ software analysis.
3.10. Skin Reconstruct
Skin reconstruct from RAD, NRAD and bulk SCC13 cells transfected with scramble or survivin
siRNA were obtained as previously described [51]. For dermal reconstructs, 0.5 mL of a cell free
collagen solution (1.35 mg/mL rat tail collagen type I in DMEM with 10% FCS and 1% Pen/Strep)
was added to tissue culture inserts (Transwell, Costar, Cambridge, MA, USA) in 12-well plates.
This pre-coated acellular layer was overlaid with 1 mL of fibroblasts mixed with collagen type I
solution (15 ˆ 104/mL). After 4 days of incubation at 37 ˝C, dermal reconstructs were rinsed and
equilibrated with keratinocyte medium for 1 h at 37 ˝C. SCC13 cells (25 ˆ 104 cells) were seeded onto
the concave of the dermal reconstruct, incubated for 1 h at 37 ˝C to allow attachment of the cells and
then submerged in keratinocyte medium 40 for 4 days. Finally, skin reconstructs were exposed to the
air and EGF free keratinocyte medium was changed every two days. After 12 days, skin reconstructs
were fixed with formalin for 2 h at room temperature, dehydrated and embedded in paraffin.
3.11. In Vivo Tumorigenesis
Freshly isolated human primary keratinocytes were infected twice with retroviral vectors
expressing RasG12V and IκBα or control vector (NoLacZ) (kindly provided by Prof. P.A. Khavari,
Stanford University, Stanford, CA, USA). 24 h from the last infection, cells were further transfected
with scramble or survivin siRNA, as previously indicated. 24 h post transfection, 106 cells were mixed
with 50 mL of Matrigel (BD Bioscience, San Jose, CA, USA) and injected in the dorsal fascia of recipient
CB17 SCID mice.
Tumors were harvested when they reached 1 cm diameter size for histological analysis, mitotic
index measure and immunostaining. Tumor volume was calculated by the formula (longest diameter)
ˆ (shortest diameter)2/2.
3.12. Statistical Analysis
The Student’s t-test was used to compare the average intensities of WB bands, average viabilities
and average cell counts. One (*) or two (**) asterisks indicate a significant difference, 0.01 < p < 0.05
and p < 0.01, respectively.
4. Conclusions
Overall, our data shed light on the role of survivin in the context of squamous cell
carcinoma-derived stem like cells. We found that survivin silencing decreased cell viability and
proliferation of RAD cells, which have been previously identified as cancer stem cells in cutaneous
SCC [22,25]. Unlike other KSC markers, survivin plays a critical role in both cell cycle regulation and
apoptosis [52], which are dysregulated in cancer, thus being the best candidate to drive development
of SCC in the skin. This suggests that survivin could be a key gene of skin cancer stem cells. Our study
suggests that blocking survivin could be successfully used to treat cSCC through targeting cancer stem
cells, thus inhibiting development, metastasis and recurrence of tumors [53].
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